Skip to content

    Recently Viewed

      Listening...

      Corporate

      Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

      Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnson’s Commitment to Oncology Innovation Novel Technology Platform Sets Stage for the Development of Next Generation ADCs and Targeted Oncologic Therapeutics

      Johnson & Johnson Subsidiary to Appeal Bankruptcy Court Ruling that Deprived Talc Claimants of an Equitable and Efficient Resolution

      Company Prepared to Vigorously Defend Itself in the Tort System if Required and will Combat Abuses by the Plaintiff’s Bar

      Johnson & Johnson Launches Exchange Offer for Separation of Kenvue Inc.

      Separation enhances Company focus on Pharmaceutical and MedTech Research & Development to deliver innovative and differentiated health outcomes Johnson & Johnson shareholders can exchange all, some or none of their shares of Johnson & Johnson common stock for shares of Kenvue Provides Johnson & Johnson shareholders with option for a tax-free exchange for U.S. Federal income tax purposes

      Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies

      Investigational CD20-targeted CAR-Ts Enhance Janssen’s B-cell Malignancy Portfolio Agreement Deepens Janssen’s Leadership in Oncology and Hematology, and Accelerates Commitment to Delivering Transformational Cell Therapies
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.